Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial

F Persson, P Rossing, P Vart, GM Chertow… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …
被引用次数：73 相关文章

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.

F Persson, P Rossing, P Vart, GM Chertow, FF Hou… - Diabetes …, 2021 - europepmc.org
Objective The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.

F Persson, P Rossing, P Vart, GM Chertow… - Diabetes …, 2021 - discovery.ucl.ac.uk
OBJECTIVE: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

F Persson, P Rossing, P Vart, GM Chertow… - Diabetes …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …
[PDF] academia.edu

[PDF][PDF] Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

HJL Heerspink - Diabetes Care, 2021 - academia.edu
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

F Persson, P Rossing, P Vart, GM Chertow, FF Hou… - Diabetes Care, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> OBJECTIVE</jats: title>< jats: p> The Dapagliflozin and
Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study …
[HTML] nih.gov

[HTML][HTML] Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

F Persson, P Rossing, P Vart, GM Chertow, FF Hou… - Diabetes …, 2021 - ncbi.nlm.nih.gov
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

F Persson, P Rossing, P Vart, GM Chertow, FF Hou… - Diabetes …, 2021 - research.rug.nl
OBJECTIVE: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …